Moderna (MRNA) PT Raised to $137 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $245.33 +1.34%
Rating Summary:
7 Buy, 20 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
7 Buy, 20 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Moderna (NASDAQ: MRNA) to $137.00 (from $120.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Moderna (MRNA) PT Raised to $90 at TD Cowen
- SpaceX (SPCX) PT Raised to $260 at Pivotal Research
- 3M (MMM) PT Raised to $197 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
